ImmuneOncia - Positive Trial Data, Jun 3, 2024
ImmuneOncia presented promising Phase 1a clinical trial results for IMC-002, an anti-CD47 mAb, at the ASCO Annual Meeting. The trial involved 12 patients with solid tumors, revealing a 50% disease control rate and a 33.3% clinical benefit rate, with no dose-limiting toxicities reported. AI-powered biomarker analysis by Lunit indicated higher CD47-positive macrophage density in responders. The trial demonstrated IMC-002's safety and potential efficacy, especially in hepatocellular carcinoma, supporting its further development in Phase 1b trials.
Full Article: ImmuneOncia Announces Biomarker Results from Phase 1 Clinical Trial of CD47 Antibody at ASCO
TuHURA Biosciences and Kintara Therapeutics - Positive Trial Data Jun 3, 2024
TuHURA Biosciences and Kintara Therapeutics announced positive Phase 1b trial results for IFx-2.0, a cancer vaccine, in advanced MCC and cSCC patients resistant to immune checkpoint inhibitors. The vaccine overcame resistance in 63% of MCC patients, prompting a planned Phase 3 trial with Keytruda® in late 2024.
Repare Therapeutics - FDA Fast Track Jun 4, 2024
Repare Therapeutics announced the FDA granted Fast Track designation to lunresertib combined with camonsertib for treating platinum-resistant ovarian cancer with specific genetic mutations. This combination is being evaluated in a Phase 1 trial for ovarian and endometrial cancers. Data from the trial are expected in Q4 2024. The Fast Track status aims to expedite the development and review of treatments for serious conditions, potentially providing earlier access to these therapies.
GSK - Positive Trial Data Jun 4, 2024
GSK reported that in a Phase II study, Jemperli (dostarlimab) showed a 100% clinical complete response rate in all 42 patients with locally advanced mismatch repair deficient (dMMR) rectal cancer. Conducted in collaboration with Memorial Sloan Kettering Cancer Center, the trial assessed Jemperli as a first-line therapy potentially replacing surgery, with all patients showing no evidence of tumors after treatment.
Full Article: GSK's Jemperli Shows 100% Clinical Complete Response Rate in Phase II Rectal Cancer Trial
SciTech Development - Venture Round Financing Jun 4, 2024
SciTech Development raised $3.2 million, totaling over $12 million, to fund clinical trials of ST-001 for T-cell non-Hodgkin lymphoma (T-NHL) and small cell lung cancer. Led by Storm Lake Capital and Pointe Angels, the funding supports ongoing Phase 1b studies. ST-001, with a novel nanoparticle delivery platform, has FDA Orphan Drug Designation. SciTech plans further trials and a Series A capital raise for FDA approval.
Full Article: SciTech Development Raises Additional $3.2M to Expand Clinical Trials for Cancer
Siren Biotechnology- Milestones & Achievements Jun 4, 2024
MilliporeSigma announced Siren Biotechnology as the North American winner of its 13th Advance Biotech Grant for developing a universal AAV immuno-gene therapy for cancer. Siren will receive bioprocessing products, AAV testing, and technical support to optimize their therapy. The program has supported over 40 biotech companies since 2014, with more grants to be awarded in APAC and EMEA this year.
Full Article: MilliporeSigma Announces Siren Biotechnology as Winner of its North American Advance Biotech Grant
Predictive Oncology AI-Driven Drug Discovery Jun 4, 2024
Predictive Oncology Inc. has introduced advanced 3D cell culture models to improve cancer drug discovery by replicating human tissue, potentially enhancing clinical outcome predictions and reducing development costs. Despite reporting increased revenues and ongoing net losses, the company continues to advance AI-driven research and form strategic partnerships, including those aimed at improving ovarian cancer survival predictions.
Full Article: Predictive Oncology Launches Advanced 3D Cell Culture Model
QUANTRO Therapeutics Milestones & Achievements Jun 4, 2024
QUANTRO Therapeutics has achieved a key milestone in its R&D program with Boehringer Ingelheim by successfully using its QUANTROseq® technology to meet all technical proof-of-concept goals and identify high-quality hits for a previously undruggable transcription factor. This progress advances their development of new cancer treatments, targeting crucial gene regulators often dysregulated in cancer. QUANTRO will receive a milestone payment, with the total potential transaction value exceeding EUR 500 million.
Alphamab Oncology & ArriVent - Collaboration, Jun 6, 2024
Alphamab Oncology announced a collaboration with ArriVent BioPharma to develop novel antibody drug conjugates (ADCs) using Alphamab's proprietary platforms. Under the agreement, Alphamab retains rights to develop and commercialize ADC products in Greater China, while ArriVent has exclusive rights outside this region. Alphamab will receive a non-refundable upfront payment and potential milestone payments totaling up to $615.5 million, plus tiered sales royalties. The collaboration aims to leverage Alphamab's technology and ArriVent's oncology expertise to create new cancer therapies.
Full Article: Alphamab Oncology Collaborated with ArriVent in Relation to the Research Development and Commercialization of ADC Products
Kiromic BioPharma - Positive Trial Data, Jun 6, 2024
Kiromic BioPharma's Deltacel-01 Phase 1 trial for stage 4 metastatic NSCLC reports a 13% tumor size reduction and no new lesions in the first patient after six months, with no dose-limiting toxicities. CEO Pietro Bersani emphasized the promising potential of their Gamma Delta T-cell therapy. Further patient results are expected by the end of June.
Full Article: Kiromic BioPharma Reports Six-Month Results from First Patient Enrolled in Deltacel-01 Clinical Trial
Theralase - Positive Trial Data, Jun 6, 2024
Theralase Technologies announced that its compound Rutherrin showed preclinical success in destroying Non-Small Cell Lung Cancer (NSCLC) in mice, significantly delaying tumor progression and improving survival rates. The company plans to start Phase Ia clinical trials for GBM and NSCLC in late 2024, with potential expansion to other cancers.
Full Article: Theralase R Successfully Destroys Lung Cancer
AstraZeneca - Positive Trial Data, Jun 6, 2024
The European Medicines Agency's committee recommended AstraZeneca's Tagrisso as part of a combination treatment for advanced lung cancer patients with specific mutations. This first-line option, alongside chemotherapy, showed a 38% reduction in disease progression or death risk compared to Tagrisso alone, based on results from the FLAURA2 trial. If approved, this enhances Tagrisso's role in treating EGFR-mutated lung cancer.
Full Article: AstraZeneca's Tagrisso Combination Receives CHMP Recommendation for Advanced Lung Cancer
Plus Therapeutics - Executive Changes & Funding, Jun 7, 2024
Plus Therapeutics appointed Dr. Greg Fuller as VP of Medical Affairs and received a $3.3 million advance from a $17.6 million CPRIT award for developing its CNSide diagnostic and rhenium (Re186) obisbemeda treatment for leptomeningeal metastases (LM). CNSide, with over 90% sensitivity, is set for commercial launch by Q4 2024. Dr. Fuller was granted options for 13,116 shares, vesting over four years.
Full Article: Plus Therapeutics Expands Management Team and Reports $3.3M Advance Payment from CPRIT
Oncology News - Market Forecast, Jun 7, 2024
The European antibody drug conjugates market, valued at US$ 2.26 billion in 2022, is projected to reach US$ 7.94 billion by 2030, growing at a CAGR of 17%. Increasing investments in ADC development are driving market growth, with significant collaborations and partnerships observed. For instance, Evotec SE invested in Tubulis GmbH for ADC development, while Spirea Limited received investments for a new generation of ADC. Strategic agreements, like AstraZeneca's collaboration with KYM Biosciences Inc. for CMG901 in gastric cancer treatment, are further propelling market expansion. Germany dominated the market in 2022, with key players including ADC Therapeutics, Pfizer, and Hoffmann-La Roche.
Elicio Therapeutics - Positive Trial Data, Jun 7, 2024
Elicio Therapeutics' preliminary data from the AMPLIFY-7P Phase 1a Study of ELI-002 7P in mKRAS-driven solid tumors showed promising results, with the drug well-tolerated and T cell responses correlating with reduced tumor biomarkers at the Phase 2 dose. ELI-002 targets cancers with mutations in the mKRAS-gene and generated an mKRAS-specific T cell response in all patients, including those with diverse mutations. These findings, presented at the ASCO Annual Meeting, highlight the drug's potential for addressing KRAS-mutated cancers.
Full Article: Elicio Therapeutics Unveils Promising Phase 1a Data for ELI-002 7P in mKRAS Tumors
